Editing NCI-H460 Large-cell Lung Carcinomar Cells(NCI-H460)

Content that violates any copyrights will be deleted. The content must be verifiable. Work submitted to CLOUD-CLONE can be edited, used, and redistributed — by anyone — subject to certain terms and conditions.

Item Name
Abbreviation
Synonyms
CAS
HGNC
MGI
PubMed
RGD
UniProt
Wiki
Summary	<p><span >Large cell lung carcinoma (LCLC) is an exceptionally aggressive disease with a poor prognosis. At present, little is known about the molecular pathology of LCLC.</span></p><p >The mutation pattern is determined by the predominance of A &gt; C mutations. Genes with a significant non-silent mutation frequency (FDR) &lt; 0.05) include TP53 (47.5%), EGFR (13.6%) and PTEN (12.1%). Moreover, PI3K signaling (including EGFR, FGRG4, ITGA1, ITGA5, and ITGA2B) is the most mutated pathway, influencing 61.9% (73/118) of the LCLC samples. The cell function test confirmed that the potential carcinogenic mutation of PI3K pathway had a more malignant cell function phenotype. Multivariate analysis further revealed that patients with the PI3K signaling pathway mutations have a poor prognosis (<em >P</em> = 0.007).These results initially identified frequent mutation of PI3K signaling pathways in LCLC and indicate potential targets for the treatment of this fatal type of LCLC.</p>
Contacts	(Please send us your contacts, e.g.: email@google.com and your other information)
More advices
CheckCode